$MNKD

Binder Steven B. sold $128K of MNKD

Binder Steven B. sold 39,051 shares of MANNKIND CORP (MNKD) at $3.29 ($0.13M total) on 2026-09-25 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Binder Steven B.
Published Sep 29, 2026, 12:26 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 29, 2026, 2:52 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$MNKD
Neutral
high confidence
Mentioned
$MNKD
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MNKDNeutralLow
01

Why it matters

A modest insider sell may cause short‑term price softness, but the overall impact is limited given the small dollar amount.

02

Market read

Primary disclosure of a small insider sale; low trading relevance.

03

What to watch

The director remains a large holder (over 700k shares), suggesting continued confidence.

Relevance 3/10Novelty 3/10Timing: after‑hours filing

Background

SEC Form 4 filing discloses insider transactions; such filings are required to be reported promptly.

Company-level read

Ticker impact

$MNKDNeutralHigh confidence
Context

Director Binder Steven B. sold 39,051 shares for $128,477 via a 10b5‑1 plan, reducing his stake to 713,258 shares.

Expected impact

likely slight downward pressure as the market prices in the insider sell

Evidence & confidence

Form 4 is a primary source; the transaction size is modest, so impact is limited.

Market effects

Minimal; ManKind operates in the cannabis sector, but a small insider sale does not affect sector outlook.

None; the filing is company‑specific.

None

Counterpoint

The sale could be routine under a pre‑arranged plan and not indicative of future weakness.

Key entities

  • ManKind Corp.

    US‑listed cannabis company (ticker MNKD).

  • Binder Steven B.

    Director of ManKind Corp.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$MNKDMedAI 8/10

MannKind Advances Inhaled IPF Drug to Global Phase 2, Eyes FUROSCIX Growth

MannKind (MNKD) advances inhaled IPF drug to global Phase 2, with potential human testing by year-end. CEO Castagna highlights FUROSCIX's strong adoption, shifting sales focus to nephrology. Company reports sufficient cash for growth, aiming for profitability next year. Vicore Pharma's Phase 2b study for IPF treatment expected to report results in summer 2025.

$MNKDMedAI 8/10

A heart-failure injector delivers a full dose in under 10 seconds. Urine output was similar to treatment into a vein.

MannKind (MNKD) presented clinical data at HFSA 2026 showing Furoscix ReadyFlow's comparable urine output to IV furosemide. The autoinjector delivers an 80 mg/mL dose in under 10 seconds, with 91.3% and 92.7% bioavailability in thigh and upper-arm injections, respectively. ReadyFlow received FDA approval in July 2026 for fluid overload treatment in heart failure or CKD patients.